Clinical trials: DAPT(Dual Antiplatelet Therapy)
Gastro Intestinal Bleeding, Ischaemic Heart Diseases
Gastrointestinal Bleeding is Blood Loss in the Digestive Tract, Classified as Upper or Lower. Ischemic Heart Disease is Due to Blocked Heart Arteries. Antiplatelet Drugs Help Prevent Heart Attacks But Increase GI Bleeding Risk, Especially When Used Together as Dual Therapy.
Gastrointestinal bleeding is blood loss in the digestive tract, classified as upper or lower. Ischemic heart disease is due to blocked heart arteries.
- Conditions
- Gastro Intestinal Bleeding, Ischaemic Heart Diseases, Antiplatelet Drugs, Antiplatelet Drug-related Gastrointestinal Injury
- Trial name
- NCT07125651
- Volunteers
- 112 people
- Sponsor
- Assiut University
Acute Coronary Syndrome
DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid
Among patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and stent implantation, 17.5% are both at high bleeding risk (HBR) and have undergone complex PCI, which also places them at…
- Trial name
- BETA-DAPT (NCT07391358)
- Testing
- Patient decision aid to support shared decision-making between patients and clinicians
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Montreal Heart Institute
Cardiovascular Disease (CVD), Stroke
A Genomic Approach for Clopidogrel in Caribbean Hispanics
Clopidogrel is a prescription medicine used to minimize blood clot formation in patients with cardiovascular disease, particularly those undergoing heart catheterization and stroke.
- Conditions
- Cardiovascular Disease (CVD), Stroke, Acute Coronary Syndrome, Peripheral Arterial Disease
- Trial name
- NCT03419325
- Testing
- CYP2C19 test, P2RY12 assay
- Where
- 2 sites in Puerto Rico
- Volunteers
- 150 people
- Sponsor
- University of Puerto Rico
Atrial Fibrillation, Coronary Artery Disease
LAAO With DAPT Versus Antithrombotic Therapy
This study will retrospectively review and compare clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation…
- Trial name
- NCT03310801
- Testing
- ACP or Watchman
- Volunteers
- 480 people
- Sponsor
- Korea University Anam Hospital
Coronary Artery Lesions
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary…
- Trial name
- NCT03218787
- Testing
- XIENCE, DAPT
- Where
- 101 sites in United States
- Volunteers
- 2,047 people
- Sponsor
- Abbott Medical Devices
Peripheral Artery Disease
Effects of Prolonged DAPT After Lower Extremity Percutaneous Transluminal Angioplasty (PTA) in Patients With LE-PAD
The objective of the present study was to evaluate the prognostic impact of prolonged dual antiplatelet therapy (DAPT) with acetylsalicylic acid plus clopidogrel on the incidence of major adverse cardiovascular events and major…
- Trial name
- LONGDAPTPAD (NCT02798913)
- Testing
- Short DAPT, Long DAPT
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Federico II University
Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease
The objective of study is to evaluate the efficacy and safety of short duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease.
- Trial name
- DAPTShort (NCT06075420)
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Genoss Co., Ltd.
Acute Coronary Syndrome (ACS)
OPTImal Management of Antithrombotic Agents: OPTIMA-5
This is a prospective, randomized, open-label clinical trial which will enroll 80 acute coronary syndrome (ACS) patients after Percutaneous Transluminal Coronary Intervention (PCI) in China.
- Trial name
- NCT04116931
- Testing
- Switch ticagrelor to clopidogrel
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Coronary Heart Disease
Pharmacodynamic and Short-term Effects of Half-dose Ticagrelor With or Without Aspirin vs DAPT From Day of PCI in CCS
Six months of aspirin plus clopidogrel remains the recommended antiplatelet regimen after percutaneous coronary intervention (PCI) for chronic coronary syndrome (CCS), with the more potent P2Y₁₂ inhibitors reserved for the acute…
- Trial name
- NCT07622056
- Testing
- Aspirin 100 mg + clopidogrel (300 mg load → 75 mg daily) ×6 months, then aspirin monotherapy, Aspirin 100 mg + ticagrelor (90 mg load → 45 mg twice daily) ×6 months, then aspirin monotherapy, Ticagrelor (90 mg load → 45 mg twice daily) monotherapy; aspirin stopped at day 2 after randomisation; continued indefinitely
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation)
Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial
Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.
- Conditions
- Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation), Aspirin, DAPT(Dual Antiplatelet Therapy)
- Trial name
- NCT06007222
- Testing
- Aspirin group, Non-antithrombotic group
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- OCEAN-SHD Study Group
Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR)
Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
Patients with acute coronary syndrome (ACS) who have both high ischemic risk and high bleeding risk represent a challenging population following percutaneous coronary intervention (PCI), as prolonged dual antiplatelet therapy…
- Conditions
- Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR), Coronary Artery Disease (CAD)
- Trial name
- NCT07374718
- Testing
- IVUS-guided BioFreedomTM Drug-Coated Stent Implantation + 1-Month DAPT Followed by 11-Month P2Y12 Inhibitor Monotherapy, Angiography-guided Conventional Drug-Eluting Stent Implantation + 12-Month Dual Antiplatelet Therapy (Aspirin + P2Y12 Inhibitor)
- Where
- China
- Volunteers
- 468 people
- Sponsor
- Shenyang Northern Hospital
ST Elevation Myocardial Infarction
STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT
Primary percutaneous coronary intervention (PCI) is the preferred revascularization strategy for patients with acute ST-segment elevation myocardial infarction (STEMI).
- Trial name
- STARS DAPT (NCT05785897)
- Testing
- Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation
- Where
- 2 sites in Switzerland
- Volunteers
- 350 people
- Sponsor
- IGLESIAS Juan Fernando
Acute Coronary Syndrome, Myocardial Infarction
Future Optimal Research and Care Evaluation
Rationale: Acute coronary syndrome (ACS) is the leading cause of death worldwide. To improve cardiovascular care, research is needed.
- Trial name
- FORCE-ACS (NCT03823547)
- Where
- 4 sites in Netherlands
- Volunteers
- 99,999 people
- Sponsor
- J.M. ten Berg
Acute Coronary Syndrome, Acute Myocardial Infarction
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute…
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- STOPDAPT-2 ACS (NCT03462498)
- Testing
- 1-months DAPT, 12-month DAPT
- Where
- Japan
- Volunteers
- 3,008 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Bleeding
Evaluation of Platelet Aggregability in the Release of CABG in Patients With ACS With DAPT.
The purpose of this study is to assess platelet aggregability by a "point of care" device (Multiplate®) to decrease the release time for coronary artery bypass graft (CABG ) in patients with acute coronary syndrome (ACS) in use…
- Trial name
- NCT02516267
- Testing
- Multiplate ADP®
- Where
- Brazil
- Volunteers
- 190 people
- Sponsor
- University of Sao Paulo General Hospital
Coronary Artery Disease
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Trial name
- SWAP-AC (NCT04006288)
- Testing
- Clopidogrel, Prasugrel, ticagrelor
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Coronary Artery Disease, Myocardial Ischemia
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
This study is a prospective, multicenter, parallel, open-label, randomized, controlled, superiority trial. It is planned to recruit 8,250 patients with multi-vessel disease(MVD), and the patients will be followed-up for at least…
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases
- Trial name
- NCT04624854
- Testing
- Clopidogrel and aspirin dual-antiplatelet therapy, Aspirin monotherapy
- Where
- 97 sites in China
- Volunteers
- 8,250 people
- Sponsor
- Harbin Medical University
High Bleeding Risk Patients, Cardiology
Dual Anti-Platelet Optimized Stent for High Bleeding Risk Patient
High risk of bleeding (HBR) is a determining factor for the duration of dual antiplatelet therapy (DAPT). Recent studies have shown that the use of one-month DAPT is beneficial in terms of ischemic as well as hemorrhagic events…
- Conditions
- High Bleeding Risk Patients, Cardiology, Stent Implantation, DAPT(Dual Antiplatelet Therapy)
- Trial name
- DIOHR (NCT07140133)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- University Hospital, Grenoble
Acute Coronary Syndrome, Myocardial Infarction
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
The optimal antithrombotic management in patients with coronary artery disease (CAD) and concomitant atrial fibrillation (AF) is unknown.
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation, Atrial Flutter
- Trial name
- WOEST-3 (NCT04436978)
- Testing
- 30-day DAPT, Guideline-directed therapy
- Where
- 20 sites in Belgium, Netherlands
- Volunteers
- 2,000 people
- Sponsor
- St. Antonius Hospital
Coronary Artery Disease
1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials
Prospective, multicenter, randomized, double-blind, placebo-controlled trials.
- Trial name
- NCT03971500
- Testing
- AntiPlatelet therapy, Percutaneous coronary intervention
- Where
- China
- Volunteers
- 3,710 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University